Search
Selected Filters
Filter Results
Displaying 11–20 of 25 news results
-
Feb 3, 2020
7th Annual Retinal Cell and Gene Therapy Innovation Summit
Please note that the seventh annual Retinal Cell and Gene Therapy Innovation Summit previously scheduled for Friday, May 1st, 2020 in Baltimore, Maryland has been cancelled.
-
Jan 29, 2020
VISIONS 2020 Conference registration now open
The Foundation Fighting Blindness VISIONS 2020 conference will be held on June 18-20th at the Hyatt Regency Minneapolis.
-
Aug 16, 2019
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Jul 11, 2019
Sustained Suppression of VEGF: Looking Forward and Looking Back
The results of the LADDER trial demonstrate a major step forward but introduce many questions.
-
Jul 11, 2019
Gene Therapy Trials for Wet Age-Related Macular Degeneration
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
-
Jun 3, 2019
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Mar 7, 2019
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Age-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
Oct 18, 2018
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
More than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
-
Jan 18, 2018
The Assistance Fund Opens New Program for Inherited Retinal Diseases
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
-
Oct 12, 2017
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
- Previous page
- page 1
- page 2
- page 3
- Next page